Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children
NCT ID: NCT00830141
Last Updated: 2015-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
259 participants
OBSERVATIONAL
2009-01-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Working hypothesis and aims: We hypothesize that mutations in ghrelin or in its receptor, GHSR, affect appetite regulation and cause growth and eating disorders.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents
NCT00140842
Effect of a Test Meal on Satiation Hormones in Obese and Normal Weight Adolescents
NCT02020395
The Association of Hormones and Peptides With Nutritional Consequences in Children With Feeding Difficulty.
NCT03045978
Acylated Ghrelin Response to Acute Exercise in Obesity
NCT00486161
Growth Hormone Secretion Following the Anaerobic Exercise
NCT01934270
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Working hypothesis and aims: We hypothesize that mutations in ghrelin or in its receptor, GHSR, affect appetite regulation and cause growth and eating disorders.
Methods: A total of 250 children followed in the pediatric endocrine department at Ha'Emek Medical Center will be divided into four groups: 50 children with GH deficiency, 50 obese children, 50 children with failure to thrive (FTT),and 50 children with idiopathic short stature (ISS). In addition, 50 children without growth or weight disorders will be included as a control group.
Genomic DNA will be isolated from the peripheral blood by standard methods. The corresponding intron-exon boundaries of the ghrelin and GHSR genes will be analyzed by direct sequencing using an ABI Prism 3100 DNA Analyzer.
Expected results: We anticipate that mutations in ghrelin or its receptor will affect growth and appetite regulation.
Importance: The findings of this study will expand our understanding of ghrelin's role in growth and appetite regulation.
Probable implications for medicine: The development of more specific therapeutic modalities for the treatment of short stature and obesity in children may become possible.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
50 children with GH deficiency
No interventions assigned to this group
2
50 children with ISS
No interventions assigned to this group
3
50 children with FTT
No interventions assigned to this group
4
50 children with obesity
No interventions assigned to this group
5
50 children without short stature or obesity will serve as controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group 2:Children with height less than the 3rd centile without any etiology
* Group 3:children with failure to thrive until the age of 3 years.
* Group 4: children with obesity defined by BMI above the 90th centile for age and sex.
* Group 5: children with no endocrine diseases and without obesity or short stature.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yardena Tenenbaum-Rakover
Head of Pediatric Endocrinology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yardena Tenenbaum-Rakover, MD
Role: PRINCIPAL_INVESTIGATOR
Ha"Emek Medical Center, Afula, ISRAEL
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0040-08-EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.